Group 1: Company Announcements - Heng Rui Medicine has received the clinical trial approval notice for HRS-4729 injection, a self-developed peptide drug targeting GLP-1R, GIPR, and GCGR receptors, with no similar products approved in the market [1] - Hubei Yihua has successfully launched its 200,000 tons/year caustic soda project, aimed at upgrading its chlor-alkali chemical industry and enhancing market competitiveness [2] - Ji Min Health announced that its shareholder, Shuangge Group, plans to reduce its stake by up to 3%, equating to a maximum of 15.75 million shares [3] - China Shipbuilding intends to absorb and merge with China Shipbuilding Industry Corporation through a share exchange, with the latter's A-shares set to be delisted on September 5, 2025 [4] - Changfei Fiber reported that its shareholder, Changjiang Communication, plans to reduce its stake by up to 0.15%, totaling no more than 1.1 million shares [5] Group 2: Strategic Collaborations and Developments - Beijing Lier has signed a strategic cooperation agreement with SenseTime and Xiwang Technology to explore AI computing power collaboration and related applications [6] - Junsheng Electronics is collaborating with leading clients like Zhiyuan Robotics, having achieved bulk supply of customized main control boards and various sensors [7][8] - Guoxin Technology has successfully tested a new generation of high-performance chips for automotive electronic BLDC motor control, aimed at addressing the MCU chip shortage in the automotive sector [9] Group 3: Other Corporate Actions - Guoguang Chain's actual controller plans to reduce their stake by up to 2.99%, totaling a maximum of 12.506 million shares [10] - Zhonghuan Hailu has terminated its control change plan, with its stock set to resume trading on September 5, 2025 [11] - Various companies have reported significant project wins, including Ningbo Construction winning contracts worth 1.117 billion yuan [12]

Group 1 - The core point of the article is that Lianhuan Pharmaceutical (600513) announced the approval of a drug registration certificate for Amlodipine Besylate Tablets by the National Medical Products Administration [1] Group 2 - The approved drug is Amlodipine Besylate Tablets, which is a medication used to treat high blood pressure and other cardiovascular conditions [1]

Group 1 - The core point of the article is that Lianhuan Pharmaceutical has received approval from the National Medical Products Administration for its product "Amlodipine Besylate Tablets" through its subsidiary [1] - Lianhuan Pharmaceutical's revenue composition for the year 2024 is as follows: 59.36% from pharmaceutical distribution, 40.38% from pharmaceutical manufacturing, and 0.26% from other businesses [1] - As of the report date, Lianhuan Pharmaceutical has a market capitalization of 6 billion yuan [1]

证券代码：600513 证券简称：联环药业 公告编号：2025-068 江苏联环药业股份有限公司 关于控股子公司获得《药品注册证书》的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 江苏联环药业股份有限公司（以下简称"公司"）控股子公司新乡市常乐 制药有限责任公司（以下简称"常乐制药"）于近日收到国家药品监督管理局 （以下简称"国家药监局"）核准签发的《药品注册证书》，现将相关情况公 告如下： | 药品名称 | 苯磺酸氨氯地平片 | | | --- | --- | --- | | 剂型 | 片剂 | | | 规格 | 5mg（按 C₂₀H₂₅ClN₂O₅计） | 10mg（按 C₂₀H₂₅ClN₂O₅计） | | 申请事项 | 药品注册（境内生产） | | | 注册分类 | 化学药品 4 类 | | | 处方药/非处方药 | 处方药 | | | 受理号 | CYHS2401760 | CYHS2401762 | | 证书编号 | 2025S02644 | 2025S02645 | | 药品批准文号 | 国药准字 H202 ...

Core Viewpoint - The company has received approval from the National Medical Products Administration for its subsidiary's drug, Amlodipine Besylate Tablets, which is commonly used to regulate vascular pressure [1] Group 1 - The drug Amlodipine Besylate Tablets has been officially registered, indicating a significant milestone for the company [1] - The approval enhances the company's product portfolio in the cardiovascular medication sector [1] - Amlodipine Besylate Tablets are recognized as a standard treatment for managing blood pressure [1]

Core Viewpoint - The company has received approval from the National Medical Products Administration for the registration of Amlodipine Besylate Tablets, which is a commonly used medication for regulating vascular pressure [1] Group 1 - The approved product is Amlodipine Besylate Tablets with specifications of 5mg and 10mg [1] - The approval was granted to the company's subsidiary, Xinxiang Changle Pharmaceutical Co., Ltd. [1] - This medication is significant in the treatment of hypertension and related cardiovascular conditions [1]

Core Viewpoint - The approval of the drug "Amlodipine Besylate Tablets" by the National Medical Products Administration is expected to enhance the product line and market competitiveness of the company and its subsidiary, but it is not anticipated to have a significant impact on recent operating performance [1] Group 1: Product Approval - The company's subsidiary, Xinxiang Changle Pharmaceutical Co., Ltd., has received the drug registration certificate for Amlodipine Besylate Tablets, with specifications of 5mg and 10mg [1] - The total sales revenue for Amlodipine Besylate Tablets in hospitals nationwide for the year 2024 is projected to reach 1.216 billion yuan [1] Group 2: R&D Investment - Changle Pharmaceutical's research and development investment for this drug approval is approximately 3.83 million yuan [1]

Group 1 - The core point of the article is that Lianhuan Pharmaceutical (600513.SH) announced that its subsidiary, Xinxiang Changle Pharmaceutical Co., Ltd., has received the drug registration certificate from the National Medical Products Administration for Amlodipine Besylate Tablets, a commonly used medication for regulating vascular pressure [1] Group 2 - The drug Amlodipine Besylate Tablets is recognized for its role in managing blood vessel pressure, indicating its significance in the pharmaceutical market [1]

Core Viewpoint - The company has received approval from the National Medical Products Administration for its drug, Amlodipine Besylate Tablets, which is commonly used to regulate vascular pressure [1] Company Summary - The company's subsidiary, Xinxiang Changle Pharmaceutical Co., Ltd., has been granted a drug registration certificate for Amlodipine Besylate Tablets [1] - Amlodipine Besylate Tablets are recognized as a standard medication for managing blood vessel pressure [1]

Core Viewpoint - Lianhuan Pharmaceutical's stock has experienced significant fluctuations, with a year-to-date increase of 119.12%, but a recent decline in the last five trading days by 5.99% [1][2]. Group 1: Stock Performance - As of September 3, Lianhuan Pharmaceutical's stock price was 21.52 CNY per share, with a market capitalization of 6.143 billion CNY [1]. - The stock has seen a trading volume of 289 million CNY and a turnover rate of 4.61% [1]. - The company has appeared on the "Dragon and Tiger List" nine times this year, with the most recent appearance on August 21, where it recorded a net buy of -44.74 million CNY [1]. Group 2: Financial Performance - For the first half of 2025, Lianhuan Pharmaceutical reported a revenue of 1.285 billion CNY, representing a year-on-year growth of 14.12% [2]. - The net profit attributable to shareholders was -40.03 million CNY, a decrease of 163.65% compared to the previous period [2]. Group 3: Shareholder Information - As of June 30, 2025, the number of shareholders was 30,100, a decrease of 0.72% from the previous period [2]. - The average number of circulating shares per shareholder increased by 0.72% to 9,485 shares [2]. - The company has distributed a total of 343 million CNY in dividends since its A-share listing, with 111 million CNY distributed in the last three years [3].